B-cell lymphoma diagnostic study of choice

	B-cell lymphoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating B-cell lymphoma from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
Echocardiography and Ultrasound
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
B-cell lymphoma diagnostic study of choice On the Web
Most recent articles
cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of B-cell lymphoma diagnostic study of choice All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on B-cell lymphoma diagnostic study of choice
CDC on B-cell lymphoma diagnostic study of choice
B-cell lymphoma diagnostic study of choice in the news
Blogs on B-cell lymphoma diagnostic study of choice
Directions to Hospitals Treating B-cell lymphoma
Risk calculators and risk factors for B-cell lymphoma diagnostic study of choice

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Adnan Ezici, M.D [2]

Overview

B-cell lymphomas include both Hodgkin's lymphomas and most Non-Hodgkin lymphomas.

Excisional lymph node biopsy is the gold standard test for the diagnosis of B-cell lymphomas. It is the preferred method to protect the architecture of lymph nodes, which is crucial for pathological evaluation and classification of lymphoma.^[1]^[2]^[3]^[4]
Fine-needle aspiration or core-needle biopsy specimens are usually insufficient because these methods have a low ratio of malignant cells and they do not sufficiently preserve the architecture of lymph nodes.
Diagnostic studies of B-cell lymphomas include light microscopic evaluation of pathologic sample, as well as an immunophenotypic analysis with immunohistochemistry to determine the subtype.

The following findings on pathological evaluation are confirmatory for Hodgkin's lypmhoma:^[4]
- Reed-Sternberg cells (RS)
- Lymphocyte predominant cells (LP)
The following findings on immunophenotypic analysis are confirmatory for the following types of non-Hodgkin's lypmhoma:^[5]^[2]
- MYC-IGH rearrangement detected by FISH in the presence of a BCL2 negative germinal centres phenotype is definitive for the diagnosis of Burkitt lymphoma.
- A disrupted structure of follicle center by sheets of large cells which are positive for pan-B-cell antigens (e.g., CD20, CD79a) is definitive for the diagnosis of diffuse large B-cell lymphoma (DLBCL).^[6]
- A chromosomal translocation t(11:14) is definitive for the diagnosis of mantle cell lymphoma.^[7]

↑ Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL (July 2020). "Hodgkin lymphoma". Nat Rev Dis Primers. 6 (1): 61. doi:10.1038/s41572-020-0189-6. PMID 32703953 Check |pmid= value (help).
↑ ^2.0 ^2.1 . PMID 27466666. Missing or empty |title= (help)
↑ Jiang M, Bennani NN, Feldman AL (May 2017). "Lymphoma classification update: B-cell non-Hodgkin lymphomas". Expert Rev Hematol. 10 (5): 405–415. doi:10.1080/17474086.2017.1318053. PMID 28395545.
↑ ^4.0 ^4.1 Kaseb H, Babiker HM. PMID 29763144. Missing or empty |title= (help)
↑ Sapkota S, Shaikh H. PMID 32644754 Check |pmid= value (help). Missing or empty |title= (help)
↑ Liu Y, Barta SK (May 2019). "Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment". Am J Hematol. 94 (5): 604–616. doi:10.1002/ajh.25460. PMID 30859597.
↑ Vose JM (August 2017). "Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management". Am J Hematol. 92 (8): 806–813. doi:10.1002/ajh.24797. PMID 28699667.